Fight the epidemic together
Novel Coronavirus Pneumonia (NCP) is a pneumonia caused by SARS- CoV- 2 infection.
Severe and critically ill patients often have hypoxemia and dyspnea and proper respiratory
support treatment is required.
As noted in the “Expert Consensus on the Use and Management of HFNC for Patients with
Novel Coronavirus Pneumonia”, for acute hypoxic respiratory failure, high-flow nasal O2
therapy (HFNC) has greater advantages over conventional O2 therapy.
ICU
Respiratory
department
ICU Emergency O.R. Neurology
Neurosurgery Geriatrics Cardiology Pediatrics Rehabilitation
Clinical application
Mild respiratory distress (respiratory rate >24 bpm)
ARDS and other Type I Respiratory Failure
(100 mmHg ≤ PaO2/FiO2 < 300 mmHg)
Type II Respiratory Failure
Invasive Ventilation Weaning
Return Policy
Items are sold as-is with no returns or refunds available unless explicitly stated.
Get a CPS 2-Year Protection Plan starting at $5.99. Sold separately. Learn more
